CN106729942A - 一种医用敷料及其制备方法 - Google Patents
一种医用敷料及其制备方法 Download PDFInfo
- Publication number
- CN106729942A CN106729942A CN201710154749.5A CN201710154749A CN106729942A CN 106729942 A CN106729942 A CN 106729942A CN 201710154749 A CN201710154749 A CN 201710154749A CN 106729942 A CN106729942 A CN 106729942A
- Authority
- CN
- China
- Prior art keywords
- acid
- medical dressing
- filtrate
- sodium alginate
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 235000010413 sodium alginate Nutrition 0.000 claims abstract description 29
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000000661 sodium alginate Substances 0.000 claims abstract description 28
- 229940005550 sodium alginate Drugs 0.000 claims abstract description 28
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 229920001661 Chitosan Polymers 0.000 claims abstract description 17
- 239000000843 powder Substances 0.000 claims abstract description 16
- 239000000835 fiber Substances 0.000 claims abstract description 15
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims abstract description 14
- 150000003242 quaternary ammonium salts Chemical class 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims abstract description 12
- 238000004108 freeze drying Methods 0.000 claims abstract description 7
- 239000000706 filtrate Substances 0.000 claims description 32
- 239000007788 liquid Substances 0.000 claims description 14
- 239000000047 product Substances 0.000 claims description 13
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 claims description 12
- 230000033228 biological regulation Effects 0.000 claims description 9
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 8
- 239000011246 composite particle Substances 0.000 claims description 8
- 238000007654 immersion Methods 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000002253 acid Substances 0.000 claims description 7
- 238000001035 drying Methods 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 6
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 claims description 6
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 claims description 6
- 229960003321 baicalin Drugs 0.000 claims description 6
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 claims description 6
- 238000006243 chemical reaction Methods 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 6
- 229940109262 curcumin Drugs 0.000 claims description 6
- 235000012754 curcumin Nutrition 0.000 claims description 6
- 239000004148 curcumin Substances 0.000 claims description 6
- 239000008367 deionised water Substances 0.000 claims description 6
- 229910021641 deionized water Inorganic materials 0.000 claims description 6
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 claims description 6
- 150000007524 organic acids Chemical class 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 5
- 239000000654 additive Substances 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 5
- 230000020477 pH reduction Effects 0.000 claims description 5
- 230000005855 radiation Effects 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 229910052708 sodium Inorganic materials 0.000 claims description 5
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 claims description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 claims description 3
- 238000007605 air drying Methods 0.000 claims description 3
- 229940041616 menthol Drugs 0.000 claims description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 2
- KBIWNQVZKHSHTI-UHFFFAOYSA-N 4-n,4-n-dimethylbenzene-1,4-diamine;oxalic acid Chemical compound OC(=O)C(O)=O.CN(C)C1=CC=C(N)C=C1 KBIWNQVZKHSHTI-UHFFFAOYSA-N 0.000 claims description 2
- 229920002101 Chitin Polymers 0.000 claims description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 2
- 235000021355 Stearic acid Nutrition 0.000 claims description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 2
- 235000011054 acetic acid Nutrition 0.000 claims description 2
- 235000019253 formic acid Nutrition 0.000 claims description 2
- 238000007710 freezing Methods 0.000 claims description 2
- 230000008014 freezing Effects 0.000 claims description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 2
- 239000011976 maleic acid Substances 0.000 claims description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 2
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
- 235000006408 oxalic acid Nutrition 0.000 claims description 2
- 238000009738 saturating Methods 0.000 claims description 2
- 239000008117 stearic acid Substances 0.000 claims description 2
- 239000011975 tartaric acid Substances 0.000 claims description 2
- 235000002906 tartaric acid Nutrition 0.000 claims description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 2
- 239000010450 olivine Substances 0.000 abstract description 2
- 229910052609 olivine Inorganic materials 0.000 abstract description 2
- 239000002245 particle Substances 0.000 abstract description 2
- 238000005213 imbibition Methods 0.000 abstract 1
- 239000002994 raw material Substances 0.000 abstract 1
- 230000008961 swelling Effects 0.000 abstract 1
- 208000027418 Wounds and injury Diseases 0.000 description 41
- 206010052428 Wound Diseases 0.000 description 37
- 239000000243 solution Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 12
- 239000000463 material Substances 0.000 description 11
- 235000010443 alginic acid Nutrition 0.000 description 10
- 229920000615 alginic acid Polymers 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 230000035699 permeability Effects 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 230000000052 comparative effect Effects 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 230000029663 wound healing Effects 0.000 description 7
- 239000002250 absorbent Substances 0.000 description 6
- 230000002745 absorbent Effects 0.000 description 6
- 230000006378 damage Effects 0.000 description 5
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 4
- 229940072056 alginate Drugs 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000002131 composite material Substances 0.000 description 4
- 239000000428 dust Substances 0.000 description 4
- 230000007613 environmental effect Effects 0.000 description 4
- 210000000416 exudates and transudate Anatomy 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 244000005700 microbiome Species 0.000 description 4
- 239000002504 physiological saline solution Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 241000283690 Bos taurus Species 0.000 description 3
- 206010011409 Cross infection Diseases 0.000 description 3
- 206010029803 Nosocomial infection Diseases 0.000 description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 239000002114 nanocomposite Substances 0.000 description 3
- 210000001640 nerve ending Anatomy 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- 229910017059 organic montmorillonite Inorganic materials 0.000 description 3
- 231100000241 scar Toxicity 0.000 description 3
- 229920002994 synthetic fiber Polymers 0.000 description 3
- 239000012209 synthetic fiber Substances 0.000 description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 206010021143 Hypoxia Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 229910000831 Steel Inorganic materials 0.000 description 2
- 206010053692 Wound complication Diseases 0.000 description 2
- 230000001476 alcoholic effect Effects 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 238000001354 calcination Methods 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 229920002674 hyaluronan Polymers 0.000 description 2
- 229960003160 hyaluronic acid Drugs 0.000 description 2
- 239000000416 hydrocolloid Substances 0.000 description 2
- 208000018875 hypoxemia Diseases 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- -1 polysaccharide carbohydrate Chemical class 0.000 description 2
- 239000010959 steel Substances 0.000 description 2
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 108010074860 Factor Xa Proteins 0.000 description 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- 229920000297 Rayon Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- FHKPLLOSJHHKNU-INIZCTEOSA-N [(3S)-3-[8-(1-ethyl-5-methylpyrazol-4-yl)-9-methylpurin-6-yl]oxypyrrolidin-1-yl]-(oxan-4-yl)methanone Chemical compound C(C)N1N=CC(=C1C)C=1N(C2=NC=NC(=C2N=1)O[C@@H]1CN(CC1)C(=O)C1CCOCC1)C FHKPLLOSJHHKNU-INIZCTEOSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000002439 hemostatic effect Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 210000004493 neutrocyte Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000001473 noxious effect Effects 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000001991 pathophysiological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 231100000719 pollutant Toxicity 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000008467 tissue growth Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000010455 vermiculite Substances 0.000 description 1
- 229910052902 vermiculite Inorganic materials 0.000 description 1
- 235000019354 vermiculite Nutrition 0.000 description 1
- 208000012313 wound discharge Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive bandages or dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/18—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing inorganic materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/38—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/62—Compostable, hydrosoluble or hydrodegradable materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Materials Engineering (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Medicinal Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Materials For Medical Uses (AREA)
Abstract
一种医用敷料，由壳聚糖衍生物及海藻酸钠纤维等生物原料制成，其中壳聚糖衍生物为羧甲基壳聚糖季铵盐。制备方法包括将海藻酸钠纤维酸化后制成粉末，与橄榄石或绿帘石混合，然后将混合颗粒进行溶胀，采用微波辐射、冷冻干燥的方式制成所需医用敷料。制成的医用敷料具有良好的透湿性、吸水性和保水性以及可生物降解性。
Description
技术领域
本发明涉及一种医用敷料，能够用于医疗救助领域。
背景技术
医用敷料，是包伤的用品，用以覆盖疮、伤口或其他损害的医用材料。随着对创面愈合过程的病理生理的深入研究，人们对创面愈合过程的理解也越来越深刻，从而导致了医用创面敷料的不断改进与发展。今天，新型的创面护理用敷料相对于早期而言，已经发生了革命性的变化，而且多种不同性能的医用敷料可供临床护理人员选用。目前，藻酸盐敷料是国际较为先进的医用敷料。各种医用敷料各有优缺点，（一）天然纱布是使用最早、最为广泛的一类敷料。优点：1、强大而快速吸收伤口创面渗出液2、生产加工过程比较简单；缺点：1、通透性太高，容易使创面脱水2、粘着创面，更换时会造成再次性机械性损伤3、外界环境微生物容易通过，交叉感染的机会较高4、用量多，更换频繁、费时，且患者痛苦由于自然资源的减少，纱布的成本也在逐渐增加，因此，为了避免过度利用自然资源，出现了应用高分子材料（合成纤维）加工成医用敷料，这就是合成纤维类敷料。（二）医用敷料合成纤维类敷料：这类敷料具有纱布一样的优点，如经济，并具有很好的吸收性能等，而且，有些产品还具有自粘性，使其使用起来很方便。然而，这类产品同样具有纱布一样的缺点，如通透性高、对外界环境颗粒性污染物无阻隔等。（三）医用敷料多聚膜类敷料：这是一类比较先进的敷料，具有氧气、水蒸气等气体可以自由通透，而环境中颗粒性异物如灰尘以及微生物等不能通过的特点。优点：1、阻隔环境微生物入侵创面，防止交叉感染2、有保湿性，使创面湿润，不会粘着创面，从而不会产生更换时的再次性机械性损伤3、有自粘性，使用方便，而且透明，便于观察创面情况缺点：1、吸收渗液能力差2、成本相对较高3、创面周围皮肤浸渍机会大，因此这类敷料主要是应用于术后且渗出不多的创面，或者作为其他敷料的辅助性敷料。（四）医用敷料发泡多聚体类敷料这是一类经由高分子材料（PU）发泡而成的敷料，表面常覆盖一层多聚半透膜，有些还具有自粘性。优点：1、快速而强大的渗出液吸收能力2、透性低，使创面保持湿润，避免更换敷料时发生再次性机械性损伤3、表面半透膜的阻隔性能，可防止环境颗粒性异物如灰尘和微生物的侵入，预防交叉感染4、使用方便、顺应性好，可适合身体各个部位5、隔热保温、缓冲外界冲力。缺点：1、由于太强的吸收性能，对于低度渗出创面可能会影响到自身清创过程2、成本相对较高3、因不透明，不方便观察创面（五）医用敷料水胶体类敷料：其主要成分是一种亲水能力非常强的水胶体羧甲基纤维素钠颗粒（CMC），与低过敏性医用粘胶，加上弹性体、增塑剂等共同构成敷料主体，其表面是一层具有半透性的多聚膜结构。 这种敷料与创面渗出液接触后，能吸收渗出物，并形成一种凝胶，避免敷料与创面粘着；同时，表面的半透膜结构可以允许氧气和水蒸气进行交换，但又具有对外界颗粒性异物如灰尘和细菌具有阻隔性。优点： 1、能吸收创面渗出物和一些有毒物质2、保持创面湿润，潴留创面本身释放的生物活性物质，在为创面愈合提供一个最佳的微环境外，还可以使创面愈合的过程加速3、具有清创作用4、形成凝胶，保护暴露的神经末梢，减轻疼痛，同时，更换敷料时不会造成再次性机械性损伤5、具有自粘性，使用方便6、良好的顺应性，使用者感觉舒适，而且外观隐蔽7、阻隔外界颗粒性异物如灰尘和细菌的侵入， 更换敷料次数少，从而减轻护理人员的劳动强度因加快创面愈合，可节省费用。缺点：1、吸收能力不是很强，因此对于高渗出性创面，常需要使用其他辅助敷料来加强吸收性能2、产品成本较高3、个别患者可能存在对成分过敏。医用敷料藻酸盐敷料：藻酸盐敷料是目前最先进的医用敷料之一。藻酸盐敷料其主要成分是藻酸盐，是在海藻中提取的天然多糖碳水化合物，为一种天然纤维素。藻酸盐医用敷料，由藻酸盐组成的一种高吸收性能的功能性伤口敷料。该医用膜接触到伤口渗出液后，能形成柔软的凝胶，为伤口愈合提供理想的湿润环境，促进伤口愈合，缓解伤口疼痛。作用机理：1、安全无毒性：藻酸盐医用膜是在海藻中提取的天然多糖碳水化合物，为一种天然高分子材料，对人体无任何毒性，可安全使用。2、高吸湿性：藻酸盐医用膜可吸收相当于自身重量的11倍液体。3、止血性：藻酸盐医用膜接触伤口渗液释放Ca2+，能促进凝血酶原激活物的形成，加速血凝过程。4、成胶性：吸收伤口渗出液，与渗液发生Na+/Ca2+离子交换，在创口表面形成一层稳定的网状凝胶。为伤口营造一个利于组织生长的微环境（微酸、无氧或低氧、适度湿润）。5、促进伤口愈合：微酸、无氧或低氧、适度湿润的伤口环境促进生长因子释放，刺激细胞增殖，提高表皮细胞的再生能力和细胞移动，促进伤口愈合。6、抑菌性：①、密封性好，使伤口与外界细菌隔绝；②、有害细菌被固定在纤维内部，有效抑制了有害细菌繁殖且减少细菌与创面接触的机会；③、湿润、微酸的环境有利于中性粒细胞发挥作用，增强局部杀菌能力，降低感染发生率7、减少局部疼痛：表面形成的水凝胶体有效保护神经末稍，避免外界刺激；不易与伤口粘连，易移除，减少伤口疼痛。8、减少疤痕形成：由于对创面无刺激，无损伤，所以疤痕形成少。优点：1、强大而快速吸收渗出液的能力2、形成凝胶，能保持创面湿润且不粘创面，保护暴露的神经末梢，减轻疼痛3、促进伤口愈合；4、可被生物降解，环保性能好；5、减少疤痕形成；缺点：1、大多数产品不具备自粘性，需要辅助敷料加以固定2、成本相对较高
发明内容
为解决上述技术问题，本发明采用的技术方案如下：
一种医用敷料，采用海藻酸钠纤维制成，具有生物可降解性和高吸水性。
所述医用敷料的制备方法，其特征在于：
（1）取废弃或回收的海藻酸钠纤维4~6wt%，向其中加入海藻酸钠纤维质量2～3％的透明质酸钠，使用质量分数为30~40％的有机酸溶液调节pH至5.0～5.5，随后进行加热，设定温度为60～65℃，保持温度40～50min后自然冷却至室温，过滤收集过滤物；
（2）将上述所得的过滤物放入烘箱中，在70~90℃下干燥1～3h，再将干燥后过滤物放入粉碎机中进行粉碎，过60~90目筛，将粉末按固液质量比（1.5~2.5）:（3~1）与水混合，并使用10~50wt％的醋酸溶液调节混合液pH至4.0～5.0，静置酸化处理1～3h后过滤，收集过滤物，将过滤物放入风干机中风干，风干后放入粉碎机中粉碎，过100~240目筛，得酸化海藻酸钠粉末；
（3）取40~50目橄榄石或绿帘石与步骤二制备得到的酸化海藻酸钠粉末按照1~6:6~1的质量比进行混合，随后按固液质量比（0.3~1）:（2~5）浸泡在6~10wt％的海藻酸钠溶液中，浸泡1～2h后过滤，收集过滤物进行风干，得复合颗粒；
（4）将上述复合颗粒放入搅拌器中，分别向搅拌器中顺序加入2～3wt％的羧甲基壳聚糖季铵盐、0.5～1.2wt％的溶角蛋白酶及3～4wt％的黄芩甙或姜黄素，再加入质量分数为30~40％的薄荷醇溶液浸泡混合物，搅拌直至所添加物完全溶解成层状悬浮液，把所得悬浮液置于微波反应器中，在微波辐射条件下，调节微波辐射功率为250W～600W，辐射温度为46℃～86℃，微波反应40min～110min，将产品在去离子水透析至中性，收集产品冷冻干燥，即得到所需医用敷料。
有机酸选自酒石酸 、乙酸、 甲酸 、丁二酸、草酸、乙二酸、己酸、马来酸、枸椽酸或硬脂酸。所述羧甲基壳聚糖季铵盐为O-羧甲基 -N-三甲基壳聚糖季铵盐(CMTMC)。所述冷冻干燥采用真空冷冻干燥技术，温度为-25~35℃。其中羧甲基壳聚糖季铵盐的分子量为1.7×105～1.6×106，季铵盐的取代度为75~85%，羧甲基的取代度为50~60%。
进一步地，上述医用敷料的制备方法，所得到的医用敷料具有层状结构。
进一步地，上述医用敷料的制备方法，所得到的医用敷料具有高吸水性。
进一步地，上述医用敷料的制备方法，所得到的医用敷料具有生物可降解性。
进一步地，上述医用敷料的制备方法，所得到的医用敷料具有抗菌性能。
进一步地，上述医用敷料的制备方法，所得到的医用敷料具有止血及促进伤口愈合的功能。
与现有技术相比，本发明具有以下优点：
（1）本发明使用微波辐射法能够快速获得性能良好的医用敷料，且制造过程中避免了壳聚糖衍生物、海藻酸钠等成分的破坏，保证了抗菌性、高吸水性以及可生物降解性。
（2）本发明制备出的医用敷料结合了壳聚糖衍生物、海藻酸钠、黄芩甙或姜黄素的优势，具备了优异的抗菌性能和热稳定性，同时橄榄石或绿帘石的加入使复合材料形成层状结构从而有效抑制细菌生长和防止伤口感染。
（3）本发明制备出的医用敷料克服了一般医用敷料强度差、耐久性差的问题。，以及具有非常优异的吸水、保湿和透湿性能。
具体实施方式
实施例1：
（1）取废弃或回收的海藻酸钠纤维4wt%，向其中加入海藻酸钠纤维质量3％的透明质酸钠，使用质量分数为30％的有机酸溶液调节pH至5.5，随后进行加热，设定温度为65℃，保持温度50min后自然冷却至室温，过滤收集过滤物；
（2）将上述所得的过滤物放入烘箱中，在90℃下干燥3h，再将干燥后过滤物放入粉碎机中进行粉碎，过60目筛，将粉末按固液质量比1.5:3与水混合，并使用10wt％的醋酸溶液调节混合液pH至4.0，静置酸化处理3h后过滤，收集过滤物，将过滤物放入风干机中风干，风干后放入粉碎机中粉碎，过240目筛，得酸化海藻酸钠粉末；
（3）取40目橄榄石或绿帘石与步骤二制备得到的酸化海藻酸钠粉末按照1:6的质量比进行混合，随后按固液质量比1:2浸泡在10wt％的海藻酸钠溶液中，浸泡2h后过滤，收集过滤物进行风干，得复合颗粒；
（4）将上述复合颗粒放入搅拌器中，分别向搅拌器中顺序加入3wt％的羧甲基壳聚糖季铵盐、1.2wt％的溶角蛋白酶及4wt％的黄芩甙或姜黄素，再加入质量分数为30％的薄荷醇溶液浸泡混合物，搅拌直至所添加物完全溶解成层状悬浮液，把所得悬浮液置于微波反应器中，在微波辐射条件下，调节微波辐射功率为250W，辐射温度为86℃，微波反应110min，将产品在去离子水透析至中性，收集产品冷冻干燥，即得到所需医用敷料。
实施例2：
（1）取废弃或回收的海藻酸钠纤维6wt%，向其中加入海藻酸钠纤维质量3％的透明质酸钠，使用质量分数为40％的有机酸溶液调节pH至5，随后进行加热，设定温度为65℃，保持温度40min后自然冷却至室温，过滤收集过滤物；
（2）将上述所得的过滤物放入烘箱中，在70℃下干燥1h，再将干燥后过滤物放入粉碎机中进行粉碎，过90目筛，将粉末按固液质量比2.5: 1与水混合，并使用50wt％的醋酸溶液调节混合液pH至4. 5静置酸化处理3h后过滤，收集过滤物，将过滤物放入风干机中风干，风干后放入粉碎机中粉碎，过240目筛，得酸化海藻酸钠粉末；
（3）取40目橄榄石或绿帘石与步骤二制备得到的酸化海藻酸钠粉末按照1:6的质量比进行混合，随后按固液质量比0.3:2.5浸泡在10wt％的海藻酸钠溶液中，浸泡1.2h后过滤，收集过滤物进行风干，得复合颗粒；
（4）将上述复合颗粒放入搅拌器中，分别向搅拌器中顺序加入3wt％的羧甲基壳聚糖季铵盐、1.2wt％的溶角蛋白酶及3.4wt％的黄芩甙或姜黄素，再加入质量分数为34％的薄荷醇溶液浸泡混合物，搅拌直至所添加物完全溶解成层状悬浮液，把所得悬浮液置于微波反应器中，在微波辐射条件下，调节微波辐射功率为550W，辐射温度为46℃，微波反应40min，将产品在去离子水透析至中性，收集产品冷冻干燥，即得到所需医用敷料。
比较例1：
其它同实施例1，但微波辐射功率为800w，辐射温度为90℃，微波反应时间为120min。
比较例2：
首先取废弃蚕丝，先用水将其表面洗净，再浸泡于质量分数为5％双氧水溶液中，向其中加入废弃蚕丝质量3％脱乙酰壳多糖，使用质量分数为30％的盐酸溶液调节pH至5.5，随后进行加热，设定温度为65℃，保持温度50min后自然冷却至室温，过滤收集过滤物；将所得的过滤物放入烘箱中，在90℃下干燥3h，再将干燥后过滤物放入粉碎机中进行粉碎，过80目筛，将粉末按固液比1:2与水混合，并使用质量分数为40％的磷酸溶液调节混合液pH至4.0，静置酸化处理3h后过滤，收集过滤物，将过滤物放入风干机中风干，风干后放入粉碎机中粉碎，过200目筛，得酸化蚕丝粉末；取膨胀蛭石放入煅烧炉中，在600℃下煅烧3h后随炉冷却至室温，取出放入粉碎机中进行粉碎，过50目筛，得载体颗粒，使用强力鼓风机将上述酸化后的蚕丝粉末吹入载体颗粒中，随后将载体颗粒按固液比1:5浸泡在质量分数为5％的海藻酸钠溶液中，浸泡2h后过滤，收集过滤物进行风干，得包裹载体颗粒；将所得的包裹载体颗粒与牛饲料，按质量比1:2进行混合后饲养牛，收集牛粪放入容器中，向容器中加入蒸馏水淹没牛粪5cm后，以300r/min搅拌15min后过滤，收集过滤物中的载体颗粒；将收集的载体颗粒放入玻璃容器中，分别向玻璃容器中加入收集的载体颗粒质量3％的壳聚糖、收集的载体颗粒质量1.2％的姜黄素及收集的载体颗粒质量4％的黄芩甙，再加入质量分数为50％的乙醇溶液浸泡混合物，搅拌直至所添加物完全溶解，将其移至微波反应器中，在600MHz下反应30min后置于紫外照射下，接枝改性2h，改性后过滤，得过滤物；收集过滤后的过滤物风干后放入超声振荡器中，振荡3h后过200目筛，收集过筛所得的粉末，即可得到复合抗菌纤维。将所述得到的复合抗菌纤维采用非织造技术做成医用敷料。
比较例3：
将0.2g羧甲基壳聚糖季铵盐/有机蒙脱土纳米复合材料溶于去离子水中配成20mg/mL的溶液，其中所使用羧甲基壳聚糖季铵盐的重均分子量为1.2×106，羧甲基的取代度为70%，季铵盐的取代度85%，将0.4g海藻酸钠溶于去离子水中配成40mg/mL的溶液，在搅拌的条件下，将羧甲基壳聚糖季铵盐/有机蒙脱土纳米复合材料溶液和海藻酸钠溶液均匀混合后转移至模具，此时羧甲基壳聚糖季铵盐/有机蒙脱土纳米复合材料与海藻酸钠的重量比约为1:2，浸泡于4wt%氯化钙溶液中，反应3h后冷冻干燥，即得到医用复合敷料。
对本发明提供的医用敷料实施例1-2以及比较例1-3按照 以下试验方法测定吸水倍率、吸水速率、保液能力、透湿度。测定的值是分别进行3次的平均值，其检测结果如表1所示。
吸水倍率：
在不锈钢容器中放入约10ml的生理盐水(0.9％NaCl)，将试验材料切成 4*4cm的试验片，密封于容器内保存8小时，放入容器前的试验片重量为m1(g)， 8小时后取出的试验片重量为m2(g)，吸水倍率Q＝(m2-m1)/m1。
吸水速率：
在试验片表面滴下500μl的生理盐水(0.9％NaCl)，测定液体被完全吸收的 时间。
保液能力：
在不锈钢容器中放入L1(ml)的生理盐水(0.9％NaCl)，将试验材料切成 7cm*10cm*0.1cm的试验片，密封于容器内保存8小时，取出试验片后，测量 剩余生理盐水的量L2(ml)，保液能力＝(L2-L1)/(7*10*0.1)*103(L/m3)。
透湿度：
按照GB 1037-88的杯式法进行测量。在玻璃容器中放入约10ml精馏水， 将试验材料切成直径为80mm的圆形试验片，将试验片覆盖在玻璃容器的开口 部位，以石蜡做的薄膜将玻璃容器密封，测定此时的重量W0。然后，在40℃-75％ 的恒温恒湿器中静置24小时后，准确测量放冷后的重量W1，透湿度 ＝(W1-W0)*104/A(g/m2/24h)，其中A为玻璃容器开口部的面积(cm2)。
表1 检测结果
| 吸水倍率 | 吸水速率（s） | 保液能力L/m3 | 透湿度g/m2/24h | |
| 实施例1 | 23 | 7 | 15000 | 1432 |
| 实施例2 | 28 | 9 | 12000 | 1416 |
| 比较例1 | 18 | 24 | 10000 | 980 |
| 比较例2 | 8 | 653 | 7900 | 366 |
| 比较例3 | 10 | 126 | 9800 | 478 |
Claims (7)
1.一种医用敷料，其特征在于：采用海藻酸钠纤维制成，具有生物降解性和高吸水性。
2.一种如权利要求1所述医用敷料的制备方法，其特征在于：
（1）取废弃或回收的海藻酸钠纤维4~6wt%，向其中加入海藻酸钠纤维质量2～3％的透明质酸钠，使用质量分数为30~40％的有机酸溶液调节pH至5.0～5.5，随后进行加热，设定温度为60～65℃，保持温度40～50min后自然冷却至室温，过滤收集过滤物；
（2）将上述所得的过滤物放入烘箱中，在70~90℃下干燥1～3h，再将干燥后过滤物放入粉碎机中进行粉碎，过60~90目筛，将粉末按固液质量比（1.5~2.5）:（3~1）与水混合，并使用10~50wt％的醋酸溶液调节混合液pH至4.0～5.0，静置酸化处理1～3h后过滤，收集过滤物，将过滤物放入风干机中风干，风干后放入粉碎机中粉碎，过100~240目筛，得酸化海藻酸钠粉末；
（3）取40~50目橄榄石或绿帘石与步骤二制备得到的酸化海藻酸钠粉末按照1~6:6~1的质量比进行混合，随后按固液质量比（0.3~1）:（2~5）浸泡在6~10wt％的海藻酸钠溶液中，浸泡1～2h后过滤，收集过滤物进行风干，得复合颗粒；
（4）将上述复合颗粒放入搅拌器中，分别向搅拌器中顺序加入2～3wt％的羧甲基壳聚糖季铵盐、0.5～1.2wt％的溶角蛋白酶及3～4wt％的黄芩甙或姜黄素，再加入质量分数为30~40％的薄荷醇溶液浸泡混合物，搅拌直至所添加物完全溶解成层状悬浮液，把所得悬浮液置于微波反应器中，在微波辐射条件下，调节微波辐射功率为250W～600W，辐射温度为46℃～86℃，微波反应40min～110min，将产品在去离子水透析至中性，收集产品冷冻干燥，即得到所需医用敷料。
3.如权利要求2所述的制备方法，其特征在于，有机酸选自酒石酸 、乙酸、 甲酸 、丁二酸、草酸、乙二酸、己酸、马来酸、枸椽酸 或硬脂酸。
4.如权利要求2所述的制备方法，其特征在于：所述羧甲基壳聚糖季铵盐为O-羧甲基 -N-三甲基壳聚糖季铵盐(CMTMC)。
5.如权利要求2所述的制备方法，其特征在于：得到的医用敷料具有层状结构。
6.如权利要求2所述的制备方法，其特征在于：得到的医用敷料具有生物可降解性。
7.如权利要求2所述的方法，其特征在于：所述冷冻干燥采用真空冷冻干燥技术，温度为-25~35℃。
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710154749.5A CN106729942A (zh) | 2017-03-15 | 2017-03-15 | 一种医用敷料及其制备方法 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710154749.5A CN106729942A (zh) | 2017-03-15 | 2017-03-15 | 一种医用敷料及其制备方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106729942A true CN106729942A (zh) | 2017-05-31 |
Family
ID=58962179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710154749.5A Withdrawn CN106729942A (zh) | 2017-03-15 | 2017-03-15 | 一种医用敷料及其制备方法 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106729942A (zh) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108653721A (zh) * | 2018-05-28 | 2018-10-16 | 刘河 | 水溶性姜黄素衍生物的壳聚糖载体药物及制备方法和用途 |
| CN110201216A (zh) * | 2019-07-24 | 2019-09-06 | 中国人民解放军陆军军医大学第二附属医院 | 一种用于贯穿伤快速止血材料及其制备方法 |
| CN114887108A (zh) * | 2022-04-12 | 2022-08-12 | 山东大学 | 一种具有梯度孔隙结构的海藻酸钠/壳聚糖季铵盐双交联医用敷料的制备方法 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105999367A (zh) * | 2016-08-08 | 2016-10-12 | 耿云花 | 一种外科医用敷料及其制备方法 |
-
2017
- 2017-03-15 CN CN201710154749.5A patent/CN106729942A/zh not_active Withdrawn
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105999367A (zh) * | 2016-08-08 | 2016-10-12 | 耿云花 | 一种外科医用敷料及其制备方法 |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108653721A (zh) * | 2018-05-28 | 2018-10-16 | 刘河 | 水溶性姜黄素衍生物的壳聚糖载体药物及制备方法和用途 |
| CN110201216A (zh) * | 2019-07-24 | 2019-09-06 | 中国人民解放军陆军军医大学第二附属医院 | 一种用于贯穿伤快速止血材料及其制备方法 |
| CN110201216B (zh) * | 2019-07-24 | 2021-10-08 | 中国人民解放军陆军军医大学第二附属医院 | 一种用于贯穿伤快速止血材料及其制备方法 |
| CN114887108A (zh) * | 2022-04-12 | 2022-08-12 | 山东大学 | 一种具有梯度孔隙结构的海藻酸钠/壳聚糖季铵盐双交联医用敷料的制备方法 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ahmed et al. | In-vitro and in-vivo study of superabsorbent PVA/Starch/g-C3N4/Ag@ TiO2 NPs hydrogel membranes for wound dressing | |
| AU2005329351B2 (en) | The preparing method and the use of antiseptic medical dressing. | |
| ES2286497T3 (es) | Materiales de aposito para heridas que comprenden complejos de polisacaridos anionicos con plata. | |
| KR101377569B1 (ko) | 항균성 창상 피복재 및 그 제조방법 | |
| CN104069537B (zh) | 海藻酸钠-羧甲基纤维素钠-壳聚糖伤口敷料及其制备方法 | |
| EP2695622B1 (en) | A chitosan wound dressing and its method of manufacturing | |
| AU2002365662B2 (en) | Wound dressings | |
| MX2008000969A (es) | Biomateriales a base de carboximetilcelulosa salificada con zinc asociado con derivados de acido hialuronico. | |
| CN107854716B (zh) | 一种抗菌除湿型敷料贴及其制备方法 | |
| CN106729942A (zh) | 一种医用敷料及其制备方法 | |
| CN104623718A (zh) | 壳聚糖凡士林纱布及其制备方法 | |
| KR20110114195A (ko) | 무기재료가 혼입된 애완용 하이드로겔 패치 및 그 제조방법 | |
| CN107296975A (zh) | 一种抗菌止血复合医用敷料及其制备方法 | |
| CN111481732A (zh) | 保护性伤口敷料的制备方法 | |
| JP4808402B2 (ja) | 陰イオン多糖と銀の複合体を含む創傷包帯材料 | |
| CN106729929A (zh) | 一种医用敷料贴及其制备方法 | |
| CN106178080B (zh) | 一种外科医用敷料止血贴 | |
| CN110448714B (zh) | 一种吸湿抑菌的壳聚糖/海藻酸钠交织型敷料及制备方法 | |
| Abdullah et al. | Development and evaluation of ciprofloxacin-bacterial cellulose composites produced through in situ incorporation method | |
| CN109432479B (zh) | 一种抗菌止血水胶体油纱及其制备方法 | |
| CN105999367B (zh) | 一种外科医用敷料及其制备方法 | |
| CN112741929B (zh) | 一种医用外伤止血复合敷料 | |
| Sun et al. | Development of part-dissolvable chitosan fibers with surface N-succinylation for wound care dressing | |
| Mao et al. | Nonwoven wound dressings | |
| KR100546793B1 (ko) | 키토산을 이용한 폼 드레싱재 및 이의 제조방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WW01 | Invention patent application withdrawn after publication | ||
| WW01 | Invention patent application withdrawn after publication |
Application publication date: 20170531 |